Alpha 1 lung disease is a genetic disorder that causes damage to the lungs over time. It can cause chronic lung disease in both children and adults. The condition destroys the elastic tissue in the lungs and digestive system, which makes it difficult to breathe over time and can ultimately lead to liver disease and lung failure.

The Alpha 1 lung disease market comprises products used for the treatment of genetic conditions that cause lung and liver damage such as alpha-1 antitrypsin deficiency. The commonly prescribed medications include bronchodilators, anti-inflammatory drugs, antifibrotics, intravenous augmentation therapies, and lung transplantation in severe cases. According to research, about 100,000 people in the US have been diagnosed with the deficiency but it is estimated that up to 200,000 individuals have the condition. Early diagnosis and treatment can help prevent or slow the progression of lung and liver disease. The growing awareness about genetic disorders and increasing healthcare expenditure are expected to drive the demand for alpha 1 lung disease therapies.

The Global Alpha 1 Lung Disease Market is estimated to be valued at US$ 4.99 Bn in 2023 and is expected to exhibit a CAGR of 18.9% over the forecast period 2023-2030.

Key Takeaways

Key players operating in the Alpha 1 Lung Disease market are AstraZeneca, Boehringer Ingelheim, Roche , Novartis, Pfizer, Merck, Bristol-Myers Squibb, Takeda Pharmaceutical, CSL Behring, Vertex Pharmaceuticals, Amgen, Sanofi, GlaxoSmithKline, Gilead Sciences , Eli Lilly, AbbVie, Johnson & Johnson, Teva Pharmaceutical, Audentes Therapeutics, Regeneron Pharmaceuticals. The dominance of major players is due to their strong portfolio of drugs to treat alpha1 antitrypsin deficiency.

The increasing prevalence of genetic disorders globally is driving the demand for alpha 1 lung disease therapies. As per research studies, around 1 in 1600 to 5,000 infants born globally have alpha 1 antitrypsin deficiency. Early diagnosis can help improve the condition's management.

Market Trends

Growing Focus on Gene Therapies: With advances in genetic engineering and cell and gene therapy research, several biotechs are developing gene therapy candidates for alpha1 lung disease. These therapies aim to deliver functional copies of the deficient genes to produce normal alpha1 antitrypsin proteins.


Market Opportunities

Emerging Markets: There is significant untapped growth potential in developing markets due to improving access to healthcare and growing medical needs. Leading companies can leverage partnerships to commercialize affordable medications.

Impact of COVID-19 on Alpha 1 Lung Disease Market

The COVID-19 pandemic has impacted the growth of Alpha 1 Lung Disease market significantly. The lockdowns and travel restrictions imposed globally disrupted the supply chain and delayed clinical trials. This affected the R&D activities of key players in the market. The hospitals shifted their focus towards handling the rising COVID cases which decreased the number of treatments available for Alpha 1 lung disease patients. The postponement of non-emergency medical procedures also lowered the demand for drugs and therapies related to this disease in 2020.

North America holds largest market share for Alpha 1 Lung Disease

Among regions, North America holds the major share of the global Alpha 1 Lung Disease market in terms of value as of 2023. The high prevalence of disease coupled with presence of developed healthcare infrastructure and favorable reimbursement policies drive the market growth in this region. The US accounts for around 85% of the North America market currently owing to large patient pool and increasing research activities for developing novel therapies.